drugset
Drugs / Aplidin
last change Nov 2024 re-read 3 minutes ago

Aplidin

also known as plitidepsin
Developed for
leukemia · lymphoma · prostate cancer
Investigated by
PharmaMar

Trials 2

today NCT00780975 · Ph 2 NCT00884286 · Ph 2
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00780975 Feb 2005 → Mar 2008 prostate cancer PharmaMar Terminated No outcome recorded Stop: Enrollment
Phase 2 NCT00884286 Dec 2004 → Jun 2010 leukemia, lymphoma PharmaMar Completed No outcome recorded

Press releases naming this drug 9 releases

DateIssuerRelease
2024-11-20 PharmaMar The General Court of the EU orders the European Commission to pay the costs in the Aplidin® case pharmamar.com ↗
2024-07-08 PharmaMar Aplidin® will be re-evaluated by the EMA. The European Commission revokes the decision that initially denied PharmaMar’s Marketing Authorization for Multiple Myeloma due to a conflict of interestAplidin® will be re-evaluated by the EMA. pharmamar.com ↗
2023-04-20 PharmaMar PharmaMar begins the Nereida clinical trial with plitidepsin for treating immunosuppressed patients with COVID-19 pharmamar.com ↗
2023-02-16 PharmaMar PharmaMar closes recruitment for the Phase III Neptuno trial with plitidepsin for the treatment of COVID-19 pharmamar.com ↗
2023-02-06 PharmaMar PharmaMar maintains that there was a conflict of interest in the Aplidin® (plitidepsin) case pharmamar.com ↗
2022-01-11 PharmaMar Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants pharmamar.com ↗
2021-04-29 PharmaMar PharmaMar receives authorization to initiate the Phase III NEPTUNO clinical trial with plitidepsin for the treatment of COVID-19 pharmamar.com ↗
2021-02-17 PharmaMar UK approves the initiation of the Phase III NEPTUNO clinical trial with PharmaMar’s Aplidin® (plitidepsin) for the treatment of patients with COVID-19 pharmamar.com ↗
2021-01-26 PharmaMar The Peer Review journal Science confirms the potent activity of PharmaMar’s plitidepsin against SARS-CoV-2 pharmamar.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Aplidin ClinicalTrials.gov intervention name — accepted as the source's own label NCT00780975 ↗
1

NCT00884286 ↗
Known as plitidepsin “Aplidin (plitidepsin)” NCT00780975 ↗
Route Intravenous “3-hours intravenous infusion” NCT00780975 ↗